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Poisoning with organophosphorus compounds (OPCs) is a major problem worldwide.
Standard therapy with atropine and established oxime-type enzyme reactivators
(pralidoxime, obidoxime) is unsatisfactory. In search of more efficacious broad-spectrum
oximes, new bispyridinium (K-) oximes have been synthesized, with K027 being
among the most promising. This review summarizes pharmacokinetic characteristics
of K027, its toxicity and in vivo efficacy to protect from OPC toxicity and compares
this oxime with another experimental bisquaternary asymmetric pyridinium aldoxime
(K048) and two established oximes (pralidoxime, obidoxime). After intramuscular (i.m.)
injection, K027 reaches maximum plasma concentration within ∼30 min; only ∼2%
enter the brain. Its intrinsic cholinesterase inhibitory activity is low, making it relatively
non-toxic. In vitro reactivation potency is high for ethyl-paraoxon-, methyl-paraoxon-,
dichlorvos-, diisopropylfluorophosphate (DFP)- and tabun-inhibited cholinesterase.
When administered in vivo after exposure to the same OPCs, K027 is comparable
or more efficacious than pralidoxime and obidoxime. When given as a pretreatment
before exposure to ethyl-paraoxon, methyl-paraoxon, DFP, or azinphos-methyl, it is
superior to the Food and Drug Administration-approved compound pyridostigmine and
comparable to physostigmine, which because of its entry into the brain may cause
unwanted behavioral effects. Because of its low toxicity, K027 can be given in high
dosages, making it a very efficacious oxime not only for postexposure treatment but
also for prophylactic administration, especially when brain penetration is undesirable.
Keywords: carbamates, cholinesterase, Cox analysis, obidoxime, paraoxon, pralidoxime, pyridostigmine,
prophylaxis
INTRODUCTION
Fatalities due to poisoning with organophosphorus compounds (OPCs) represent a major problem
worldwide. OPCs are used for a broad range of purposes, ranging from parasiticides, for example,
parathion, malathion, methyl-parathion, azinphos-methyl, terbufos, dichlorvos, or dicrotophos, to
flame retardants, hydraulic liquids, and additives to lubricants (Gupta, 2006a). Because they are so
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extensively used, readily available, and also easy to synthesize,
they are among the most frequent causes of accidental,
professional, and suicidal intoxications. It is estimated that the
number of fatalities per year reaches 200,000, with developing
countries being the most affected (Eddleston et al., 2008;
Chowdhary et al., 2014; King and Aaron, 2015). Moreover,
they have also been abused in malicious poisonings, terrorist
attacks, or chemical warfare (Antonijevic and Stojiljkovic,
2007; Petroianu, 2014; Myhrer and Aas, 2016; Masson and
Nachon, 2017). The main toxic mechanism of OPCs is
phosphylation (denoting phosphorylation or phosphonylation)
of acetylcholinesterase (AChE), the enzyme responsible for
hydrolyzing the neurotransmitter acetylcholine (ACh) at
cholinergic synapses. ACh is the neurotransmitter at the
neuromuscular junction of the somatic nervous system, at
sympathetic and parasympathetic ganglia of the autonomic
nervous system, at parasympathetic nerve terminals supplying
smooth muscle, cardiac muscle, and glands, and at synapses
in the central nervous system. AChE inhibition results in
the accumulation of ACh at these cholinergic synapses and
long-lasting stimulation of nicotinic and muscarinic ACh
receptors. Muscarinic signs and symptoms can be memorized
by the mnemonic DUMBBELLS (diarrhea, urination, miosis,
bronchorrhea, bronchospasms, emesis, lacrimation, laxation,
sweating); nicotinic stimulation leads to tachycardia, high blood
pressure, muscle fasciculations, and, in severe cases, paralysis
of respiratory muscles. Central nervous system symptoms
are restlessness, seizures, and coma (Eyer et al., 2003; Balali-
Mood and Balali-Mood, 2008). Death generally occurs due to
respiratory insufficiency, generalized seizures, and/or multiorgan
failure (Petroianu et al., 1998; Petroianu, 2005; Antonijevic
and Stojiljkovic, 2007; Balali-Mood and Balali-Mood, 2008;
Hrabetz et al., 2013).
Standard treatment combines, in addition to supportive
therapy, three therapeutic approaches: blocking muscarinic
stimulation by atropine, dephosphorylating inhibited AChE
by oxime-type reactivators, and controlling seizures by
benzodiazepines, for example, diazepam or midazolam.
The oxime of choice in Japan, Great Britain, the United States,
and France is pralidoxime; in the Netherlands, Finland,
Norway, and Germany, obidoxime is used; HI-6 is standard in
Sweden and Canada; and trimedoxime (TMB-4) is currently
stored in some East European countries (Stojiljkovic and
Jokanovic, 2006; Worek and Thiermann, 2013). However,
several studies cast doubt on the efficacy of these oximes,
particularly in the treatment of pesticide ingestion (Johnson
et al., 2000; Eyer, 2007; Eddleston et al., 2008; Buckley et al., 2011;
Blumenberg et al., 2018). Therefore, several research groups are
working on the synthesis of more efficacious broad-spectrum
oxime-type reactivators.
Kamil Kuca, Kamil Musilek, and their collaborators from
the Faculty of Military Health Sciences, Hradec Kralove, Czech
Republic have been among the most prolific researchers,
synthesizing hundreds of new oxime-type AChE reactivators,
which they named K-oximes after Kamil, the first name of both
Kuca and Musilek. Their first series (Kuca et al., 2003) included
bisquaternary asymmetric pyridinium aldoximes containing
two pyridinium rings that are connected by a propylene
(K027 = 1-(4-hydroxyiminomethyl–pyridinium)-3-(4-carbamoyl
pyridinium) propane) or a butylene (K048 = [1-(4-hydroxy
iminomethyl-pyridinium)-3-(4-carbamoylpyridinium) butane])
linker, one of the pyridinium rings carrying an oxime residue
in position 4, the other one a carbamoyl residue in position 4
(Figure 1). This was followed by a second series comprising
bispyridinium oximes with two aldoxime groups, either in
positions 2 and 4 (K053) or twice in position 4 of the pyridine
rings (K074 and K075) (Musilek et al., 2007b; Kuca et al.,
2009). The third series consisted of bisquaternary symmetric
pyridinium aldoximes containing a xylene linker (Musilek et al.,
2007a), with two functional aldoxime groups in position 2 (K106,
K107, K108) or position 4 (K112, K113, K114).
Over the past 15 years, in collaboration with our Czech
colleagues, we have been systematically characterizing these
novel K-oximes. We have performed in vitro essays on human
red blood cell AChE, testing the intrinsic AChE inhibitory
activity of these oximes and their reactivation efficacy. In
addition, we have determined their pharmacokinetic properties.
These studies were followed by a series of in vivo experiments
evaluating their efficacy to protect from OPC-induced mortality.
During all these studies, the “Guiding principles in the Care
of and Use of Laboratory Animals” (Council of The American
Physiological Society) have been observed, and all experiments
were performed with the approval of the Institutional Review
Board (FMHS Animal Research Ethics Committee). We have
tested these oximes, when administered immediately after
the OPC diisopropylfluorophosphate (DFP), ethyl-paraoxon,
methyl-paraoxon, and azinphos-methyl (Figure 1). DFP, a
structural analog of the nerve agent sarin, is a widely used model
compound to investigate AChE inhibition and OPC intoxications
(Antonijevic and Stojiljkovic, 2007; Lorke and Petroianu, 2019).
Ethyl-paraoxon = paraoxon is the biologically active metabolite
of parathion, one of the earliest OPC pesticides manufactured
(Konst and Plummer, 1950; Gupta, 2006b). Similarly, the
pesticide methyl-parathion (metaphos), one of the most widely
applied OPC pesticides, has to be bioactivated by CYP-dependent
oxygenases to the very efficient AChE inhibitor methyl-paraoxon
(Garcia et al., 2003; Ruckart et al., 2004; Isbister et al., 2007).
Azinphos-methyl, an organophosphorothionate (thion) globally
used as a broad-spectrum insecticide (Schulz, 2004; Stoner and
Eitzer, 2013; Belenguer et al., 2014), which hardly inhibits AChE
in its thion form, has to be metabolized in vivo by way of CYP450-
mediated oxidative desulfuration to its highly toxic phosphate
triester (oxon) form (Buratti et al., 2002). This conversion is fast,
taking less than 10 min in an in vitro liver slice model, and 5–
10 min in vivo after oral (Pasquet et al., 1976) or intraperitoneal
(Lorke et al., 2013; Petroianu et al., 2015) administration.
Better therapeutic results are achieved when reversible
AChE inhibitors are given before OPC exposure (for review,
see Lorke and Petroianu, 2019). We have, therefore, also
tested K027, when given as pretreatment before the same
OPCs (DFP, ethyl-paraoxon, methyl-paraoxon, azinphos-
methyl). Its protective efficacy was compared with that of
pyridostigmine (Figure 1), the only substance approved by the
US Food and Drug Administration (FDA) for pretreatment
when exposure to the nerve agent soman is anticipated
(US Food and Drug Administration, 2003), and of three other
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FIGURE 1 | Chemical formulas of the experimental K-oximes K027 and K048, the established oximes pralidoxime and obidoxime, the organophosphorus
compounds (OPCs) diisopropylfluorophosphate (DFP), ethyl-paraoxon, methyl-paraoxon, and azinphos-methyl, and the reversible acetylcholinesterase (AChE)
inhibitors physostigmine, pyridostigmine, tacrine, and ranitidine.
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known AChE inhibitors (physostigmine, tacrine, ranitidine)
already used clinically for other indications (reviewed in
Lorke and Petroianu, 2019). Physostigmine, the first AChE
inhibitor known to man, is a carbamate readily passing the
blood–brain barrier that has been used in the therapy of atropine
poisoning, myasthenia gravis, Alzheimer’s disease, and glaucoma
(for review, see Somani and Dube, 1989; Zhao et al., 2004). The
acridine derivative tacrine was the first AChE inhibitor developed
to improve the cognitive performance of Alzheimer’s disease
(Raina et al., 2008), and ranitidine is an inhibitor of histamine
type 2 (H2) receptors, which is widely used to reduce gastric acid
production (Grant et al., 1989).
Of the 15 evaluated K-oximes, K027 turned out to be
the most promising experimental oxime. This review
summarizes in vitro and in vivo results obtained for K027
and compares them with K048, the other experimental
bisquaternary asymmetric pyridinium aldoximes containing two
pyridinium rings, and to the most widely used established oximes
pralidoxime and obidoxime.
PHARMACOKINETICS
Plasma and brain concentrations of K027, K048, obidoxime
(Lorke et al., 2007), and pralidoxime (Petroianu et al., 2007b)
were measured by high performance liquid chromatography
(HPLC) (Gyenge et al., 2007) over a period of 10 h after
intramuscular (i.m.) injections of 50 µmol of oxime into rats
(Figure 2). Maximum plasma concentrations for pralidoxime
(Cmax = 303 µM), obidoxime (Cmax = 716 µM), and K027
(Cmax = 586 µM) were reached after 5 min (Table 1), for K048
(Cmax = 621 µM) after 15 min; plasma half-life was 40 min for
obidoxime and pralidoxime and 60 min for K027 and K048. In
the brain, maximum concentrations were reached after 15 min
for pralidoxime (Cmax = 17 µM), obidoxime (Cmax = 10 µM),
K027 (Cmax = 3.5 µM), and K048 (Cmax = 8.5 µM), with a half-
life of ∼70 min (pralidoxime), ∼60 min (obidoxime), ∼80 min
(K027), and ∼120 min (K048). The proportion of plasma oxime
entering the brain, determined as a relation between the area
under the curve (AUC) plasma and the AUC brain, was 8% for
pralidoxime, 5.5% for obidoxime, 2% for K027, and 5% for K048
(Table 1). Whereas a previous OPC (paraoxon) injection did
not significantly affect the passage of obidoxime, K027 and K048
into the brain, brain entry of pralidoxime increased from 8% to
12% if paraoxon was administered 1 min before oxime injection
(Petroianu et al., 2007b). The reasons for these differences in
brain entry, for example, lipophilicity, molecular weight, and
possible transporters, have been discussed in detail (Lorke et al.,
2008a). Elimination kinetics of K027, when injected i.m. in the
dosage of 50 µmol, have been analyzed (Tekes et al., 2006), with
the possibility of zero-order kinetics (from 15 through 120 min)
at high dosages.
In a set of subsequent studies, the pharmacokinetics of K027
have been analyzed in rats after i.m. injection of a smaller
oxime dosage (22.07 mg/kg = ∼12 µmol/rat). Maximum plasma
concentrations (Cmax = 18.6 µg/ml = 32 µM) were reached
after approximately 15 min (Karasova et al., 2013) to 30 min
(Karasova et al., 2013; Zemek et al., 2013), maximum brain
concentrations after 15–30 min, depending on the brain region
(Karasova et al., 2013), with the highest concentrations observed
in the frontal cortex and the lowest in the basal ganglia. Similar
observations were made for obidoxime; however, relatively low
concentrations were measured in the frontal cortex for HI-6
(Karasova et al., 2014). After i.m. injections of three different
K027 dosages into rats (5.0, 30, and 60 µmol/rat), maximum
plasma concentrations (Cmax =∼50 mg/L = 85 µM for 60 µmol)
were reached 5–15 min later, and maximum brain concentrations
(Cmax = ∼5 mg/L = ∼8 µM for 60 µmol) after 15–30 min
(Nurulain et al., 2013), confirming overall our previous results
(Lorke et al., 2007; Petroianu et al., 2007b). Binding of oximes
to human serum albumin has been shown to be 5% for K027,
10% for K075, 7% for obidoxime, and 1% for HI-6 (Zemek et al.,
2013). Analyzing the pharmacokinetic profile in pigs, maximum
plasma concentrations were measured 20 min after i.m. injections
of 1,500 mg/animal ( = 45 mg/kg = 78 µmol/kg body weight)
K027 (Karasova et al., 2017), and the highest concentrations
were found in the kidney and lung, whereas brain concentrations
were low, the brain/plasma ratio being about 1%. K027 is highly
concentrated in the urine (Karasova et al., 2017).
IN VITRO PARAMETERS
After the synthesis of K027 had been described in 2003 (Kuca
et al., 2003), its capacity to reactivate AChE inhibited by nerve
gases has been extensively tested in vitro on AChE derived from
rat brain homogenate. When AChE was inhibited by the nerve
agent “venomous agent X” (VX) (Kuca and Kassa, 2004b), K027
displayed a relatively low reactivation potency, similar to that
of obidoxime, methoxime, or pralidoxime and below that of
HI-6. When the ability of K027 to reactivate AChE inhibited
by the nerve agents tabun, sarin, and VX was compared with
that of pralidoxime, obidoxime, and HI-6 (Kuca and Kassa,
2004a), its reactivation potency was below that of the other
oximes for sarin-inhibited AChE, comparable to obidoxime for
reactivation of VX- and tabun-inhibited AChE, and above HI-
6 for tabun-inhibited AChE. Subsequent studies have reported
efficacy of K027 and K048 to reactivate tabun-inhibited AChE
(Kuca et al., 2005a), poor reactivation of sarin-inhibited AChE
for K027 and K048 (Kuca et al., 2005b), and reactivation potency
comparable to HI-6 for K027, when AChE was inhibited by
cyclosarin (Kuca et al., 2006). Tabun-inhibited human brain
AChE was best reactivated by K048, which was far superior to
obidoxime and trimedoxime. K027 was only able to reactivate
tabun-inhibited AChE at very high concentrations (Kuca et al.,
2007). Subsequently, a comprehensive study has evaluated the
potency of two different K027 concentrations to reactivate AChE
derived from rat brain homogenate and inhibited by the nerve
agents tabun, sarin, cyclosarin, soman, VX, or Russian VX and
by the pesticides paraoxon, dicrotophos, or methylchlorpyrifos
(Kuca et al., 2010). It was found that K027, at a concentration
of 10 µM, could only reactivate AChE inhibited by paraoxon
and methylchlorpyrifos, whereas, at a concentration of 1,000µM,
K027 also efficiently reactivated AChE inhibited by sarin, VX,
Russian VX, dicrotophos, and to a much lesser degree, also
tabun. Reactivation of cyclosarin- and soman-inhibited AChE
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FIGURE 2 | Time course of concentrations of experimental K-oximes K027 (A,B) and K048 (C,D) and the established oxime obidoxime (E,F) in plasma (A,C,E) and
brain (B,D,F) after intramuscular (i.m.) injections of 50 µmol of oxime into rats. Depicted are concentrations, when oxime was injected alone (black) or in combination
with paraoxon (POX, blue), which did not significantly influence plasma or brain concentrations of K027, K048, or obidoxime. Data from Lorke et al. (2007) and
Petroianu et al. (2007b). Image reproduced with permission of “JOHN WILEY AND SONS,” License Number: 4450270092893.
by K027 was unsatisfactory. Quantum chemical, docking, and
Steered Molecular Dynamics (SMD) analyses of K027 have
discussed the role of its propylene linker compared with the
xylene or ether linkers of other K-oximes in the reactivation of
tabun-inhibited AChE (Ghosh et al., 2017). The docking results
suggest that the oxime oxygen of K027 resides 5.12 Å away
from the phosphorus atom of the active-site serine (SUN203) of
tabun-inhibited mAChE, which is closer than K127 and K203,
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TABLE 1 | Pharmacokinetic parameters of the experimental K-oximes K024 and K048 and of the established oximes pralidoxime and obidoxime.
Oxime Cmax (Plasma) tmax (Plasma) t1/2 (Plasma) Cmax (Brain) tmax (Brain) T1/2 (brain) Proportion (brain/plasma) Injected dose
Pralidoxime 303 µM 5 min 40 min 17 µM 15 min 70 min 8% 50 µmol
Obidoxime 716 µM 5 min 40 min 10 µM 15 min 60 min 5.5% 50 µmol
K027 586 µM 5 min 60 min 3.5 µM 15 min 80 min 2% 50 µmol
K048 621 µM 15 min 60 min 8.5 µM 15 min 120 min 5% 50 µmol
Column 2 lists the maximum concentration (Cmax) measured in plasma and column 3 the time after which it is reached (tmax). Column 4 lists the half-life (t1/2) in plasma
of the respective oxime. Columns 5–7 list the same parameters for the brain and column 8 the proportion of oxime reaching the brain, determined as the area under the
concentration curve (AUC) for brain as a fraction of the AUC for plasma. Column 9 lists the dose injected intramuscularly into rats to determine pharmacokinetics. Data
from Lorke et al. (2007) and Petroianu et al. (2007b).
and the binding energy of this reactivator-protein complex is
−8.20 kcal/mol.
Reactivation potencies of K027, K048, and pralidoxime have
also been compared in vitro in human erythrocyte AChE
inhibited by DFP (Lorke et al., 2008), paraoxon (Petroianu
et al., 2012), and methyl-paraoxon (Petroianu et al., 2007a). In
general, K027 was the most efficacious reactivator; the ranking
of reactivator potencies obtained using ethyl-paraoxon as an
inhibitor was as follows: K027 > K048 > K033 > pralidoxime.
This ranking was basically the same as the one determined
for methyl-paraoxon inhibition: K027 equals K048, which
are both superior to K033, with pralidoxime being the least
efficacious oxime. When erythrocyte AChE was inhibited by DFP
(Lorke et al., 2008), oximes with a xylene linker (K107, K108,
K113) showed better in vitro reactivation, whereas reactivation
potency for K027, pralidoxime, and obidoxime was one order
of magnitude lower. The most extensive investigation has
characterized reactivation kinetics of established (pralidoxime,
obidoxime, trimedoxime, HI-6, methoxime) and experimental
(K027, K048, K074, K075, K108) oximes in human erythrocyte
AChE inhibited by tabun, cyclosarin, and paraoxon (Winter
et al., 2016). Best reactivation of paraoxon-inhibited AChE was
observed for obidoxime and trimedoxime, followed by K075,
K027, and K048, which were all superior to pralidoxime and
HI-6. Because obidoxime, trimedoxime, K075, K027, and K048
have their oxime group in position 4, it was concluded that 4-
oximes are better reactivators of paraoxon-inhibited AChE than
those with the oxime group in position 2 (Winter et al., 2016). In
contrast, K027, K048, obidoxime, trimedoxime, and pralidoxime
were poor reactivators of cyclosarin-inhibited AChE. As a general
rule, oximes with at least one oxime group in position 2 reactivate
cyclosarin-inhibited AChE better than those with the oxime
group in position 4 (Worek et al., 2012). Worek et al. (2012) also
observed that the reactivation potency of oximes with a but-2-ene
linker (K053, K075) was generally lower than the one of oximes
with an oxybismethylene linker (obidoxime, HI-6), an idea that
had already been put forward by Arthur Lüttringhaus and Ilse
Hagedorn in the 1960s (Eyer, 2007). Only very few of the tested
oximes (K074, K075, K048, trimedoxime, and to a certain degree,
also K027) were able to reactivate tabun-inhibited AChE (Winter
et al., 2016). Using a different model, electric eel AChE inhibited
by paraoxon (Gupta et al., 2014b) and DFP (Gupta et al., 2014a),
Gupta et al. have confirmed favorable reactivation kinetics of
K027 and K048, which were, however, exceeded by obidoxime
and trimedoxime (Gupta et al., 2014a).
Oximes are not only able to reactivate phosphylated AChE
but they also themselves inhibit AChE (Lorke et al., 2008), a
characteristic that is termed their “intrinsic AChE inhibitory
activity.” We have quantified the intrinsic AChE inhibitory of
K027 in vitro (Table 2) by calculating its concentration necessary
to inhibit 50% of human red blood cell AChE activity (IC50)
and compared it with that of pralidoxime, obidoxime, K048, and
other experimental K-oximes (Lorke et al., 2008). The IC50 was
measured in the presence of the selective butyrylcholinesterase
inhibitor ethopropazine (Worek et al., 1999) using the method
originally described by Ellman and subsequently improved by
Worek (Ellman et al., 1961). Enzyme activities were corrected
for oxime-induced thiocholine esteratic activity (Petroianu
et al., 2004). The IC50 of K027 (IC50 = 414 µM) and K048
(IC50 = 461 µM) was of the same order of magnitude as that of
the established oxime pralidoxime (IC50 = 592 µM) and slightly
lower than the IC50 of obidoxime (IC50 = 702 µM). Weak AChE
inhibition by K027 and K048 had been previously reported (Calic
et al., 2006). In contrast, experimental oximes with a xylene linker
(K107, K108, K113, K114) are much stronger AChE inhibitors
(IC50 between 6 and 13 µM).
TOXICITY
We have previously been able to show that oxime toxicity is
closely related to their intrinsic AChE inhibitory activity and that
the LD50 is correlated with the IC50 of AChE inhibition (Lorke
and Petroianu, 2009). Correspondingly, K027 with an LD50 of
350 µmol/animal = 612 mg/kg body weight (i.p. injection) is
the least toxic of the tested oximes in rats (Table 2), compared
with 180µmol/animal = 120 mg/kg body weight for pralidoxime,
140 µmol/animal = 246 mg/kg body weight for K048, and
132µmol/animal = 177 mg/kg body weight for obidoxime, which
is more than one order of magnitude less lethal than the oximes
with a xylene linker (LD50 = ∼3–15 µmol/animal) (Lorke and
Petroianu, 2009). Almost identical LD50 values for K027 and
K048 were reported by Berend et al. (2008), and LD50 figures
obtained for mice also came very close to our data (Kassa et al.,
2007). Slightly higher values were obtained after i.m. injections
(Antonijevic et al., 2016): 2.53 mmol/kg for K027, compared
with ∼1.4 mmol/kg for i.p. injection; 0.49 mmol/kg both for
i.m. and i.p. administration of obidoxime and 1.24 mmol/kg
for pralidoxime i.m. versus ∼0.7 mmol/kg for i.p. injection. In
addition, it needs to be taken into account that the IC50 of K027,
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TABLE 2 | Chemical and biological parameters of the experimental (K027, K048) and established (pralidoxime, obidoxime) oxime reactivators of organophosphate-
inhibited acetylcholinesterase (AChE).
Oxime Molecular weight IC50 (µM) LD01 LD50 Injected dose
(µmol/rat) (µmol/rat) (µmol/rat)
Pralidoxime 172.6 592 117 180 50
Obidoxime 359.21 702 107 132 50
K027 446.16 414 250 350 50
K048 460.16 461 110 140 50
Column 2 lists their molecular weights, column 3 their intrinsic ability to inhibit human erythrocyte AChE as quantified by the concentration necessary to inhibit 50% of
human erythrocyte AChE activity (IC50, data from Lorke et al., 2008), column 4 their LD01, and column 5 their LD50 values (Lorke et al., 2008b) for intraperitoneal (i.p).
injection in rats. Column 6 lists the doses injected i.p. within 1 min after OPC exposure in µmol/rat to test efficacy to protect from OPC-induced mortality. The injected
oxime dose is approximately half the LD01, except for K027, which was given in a smaller dosage.
determined in rat blood, is two and one half times higher than
the one determined in human blood (Lorke and Petroianu, 2009),
which may indicate higher toxicity in humans than in rats.
In comparison to oximes, OPCs are much more potent AChE
inhibitors (Table 3). AChE inhibition of the tested OPCs, with the
exception of azinphos-methyl, is about three orders of magnitude
more potent than the intrinsic AChE inhibitory activity of the
investigated oximes (for review, see Lorke and Petroianu, 2019),
with an IC50 of 15 nM for ethyl-paraoxon, 60 nM for methyl-
paraoxon, and 120 nM for DFP. The IC50 of azinphos-methyl
(189 µM) is relatively high in comparison, but it has to be kept
in mind that azinphos-methyl is a thiophosphate that needs to
be bioactivated in the liver to its oxon form to become a potent
AChE inhibitor. Correspondingly, all four OPCs have an LD50 in
the 1- to 6-µmol/animal range (Table 3).
Several in vitro studies have been performed assessing the
toxicity of K027. In addition to measuring the intrinsic AChE
inhibitory activity and LD50 values (see above), the interaction
of K027, K075 and other experimental oximes with calf thymus
DNA has been tested, and changes in cell cycle distribution,
mitochondrial membrane potential, and cell viability have been
determined in HL-60 (human acute promyelocytic leukemia)
cells (Janockova et al., 2014). In that study, K027 and K075
were found to be relatively safe from the point of view of DNA
binding, and there was no indication for cytotoxicity. Because
hepatotoxicity has been reported for several of the established
oximes (for review see Marrs, 1991), the influence of K027 on
cell viability has been tested in hepatocellular cell lines. No
prominent inhibition of the activities of human liver microsomal
cytochromes P450 by K027 was detected (Spicakova et al., 2016),
and there was no indication that K027 or pralidoxime impaired
the viability of human hepatocellular carcinoma (HepG2) cells
(Prado et al., 2015). K027 and pralidoxime had no effect
on glycolysis or oxygen consumption in HepG2 cells (Prado
et al., 2015). Moreover, these two oximes did not lead to the
generation of oxidants nor did they affect the mitochondrial
membrane potential. In addition, K027 and pralidoxime failed
to activate effector caspases (Prado et al., 2015). The same
parameters were not altered in human neuroblastoma (SH-SY5Y)
cells either, and there was no indication for neurotoxicity
other than increased ACh levels due to AChE inhibition
(Prado et al., 2015). Another study, examining the influence
of three K- (K027, K074, K075) and five established oximes
(pralidoxime, trimedoxime, obidoxime, methoxime, HI-6) on the
viability of the same hepatocellular carcinoma cells (HepG2),
did not give any indication for hepatotoxicity either (Muckova
et al., 2019). In the MTT (dimethylthiazol-diphenyl-tetrazolium
bromide) reduction assay, evaluating mitochondrial succinate
dehydrogenase activity, and the “electrical impedance based real-
time cytotoxicity assay” (Muckova et al., 2019), K027 was the least
cytotoxic oxime for hepatocyte and fibroblast cell lines and the
second least toxic oxime for adenocarcinoma cell lines. Taken
together, there is no in vitro indication that K027 is hepatotoxic
or neurotoxic, apart from its intrinsic cholinesterase inhibitory
activity due to its interaction with the catalytic site of the AChE
enzyme (Lorke et al., 2008).
In vivo studies on rats (Lorke et al., 2008) and mice (Zunec
et al., 2015) also demonstrate that K027 and K048 stand out by
their low acute toxicities. Compared with established and other
K-oximes, K027 is the least toxic, with regard to its LD50 (see
above). Histopathological evaluation of the effects of K027, HI-
6, and obidoxime on hepatic functions in rats in vivo showed
no influence of these oximes on the number of lipid droplets
in liver tissue samples, but a decrease in multidrug resistance
protein 2 immunoreaction after injection of HI-6 at a dosage
of 5% LD50 (Pejchal et al., 2008). A comparable effect was only
achieved after the injection of 50% LD50 of K027 and obidoxime.
Whereas lower doses of HI-6 and obidoxime were able to impair
hepatic transporter function, K027 only affected the transporter
at much higher concentrations (Pejchal et al., 2008).
IN VIVO PROTECTION
The efficacy of K027 to protect from tabun-induced toxicity
has been demonstrated in a number of in vivo experiments.
The efficacy of K027 and K048 to reactivate in vivo AChE
in rat blood, diaphragm, and brain tissue has been compared
with that of obidoxime, trimedoxime, and HI-6 after i.m.
injections of tabun (Kassa et al., 2006). AChE measurements
have revealed that the in vivo reactivating efficacy of K027 and
K048 is comparable to the efficacy of obidoxime and trimedoxime
and that K027 and K048 can also eliminate the acute lethal
effects of tabun (Kassa et al., 2006). Monitoring a large battery
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TABLE 3 | Chemical and biological parameters of the investigated OPCs.
Organophosphorus compound Molecular weight IC50 (µM) LD50 (µmol/rat) LD70 (µmol/rat) Injected dose (µmol/rat)
DFP 184.15 0.12 4.8 6 6, 10, 14
Ethyl-paraoxon 275.2 0.015 0.8 1 1, 5, 10
Methyl-paraoxon 247.14 0.06 1.1 1.5 2, 3, 5
Azinphos methyl 317.32 189 3.2 5 5, 10, 15
Column 2 lists their molecular weights, column 3 their concentration necessary to inhibit 50% of human red blood cell AChE activity (IC50), column 4 their LD50 values for
intraperitoneal (i.p). application in rats, column 5 their LD70 values, and column 6 the doses injected i.p. to perform a Cox (1972) analysis of the mortality-reducing efficacy
of various oximes, including K027. The administered doses are approximately LD70, LD100, and twice LD70.
of behavioral changes following administration of sublethal
tabun doses to rats, it was demonstrated that tabun-induced
neurotoxicity could be reduced, but not completely eliminated
by K027, K048, and obidoxime in combination with atropine,
whereas HI-6 was not efficacious (Kassa and Kunesova, 2006a).
Similarly, the cognitive performance after tabun exposure could
be improved by K027 plus atropine (Kassa and Kunesova, 2006b).
In addition, K027 and K048 better protected mice from tabun-
induced mortality than HI-6, whereas their mortality-reducing
efficacy on soman toxicity was inferior to that of HI-6 (Calic
et al., 2006; Berend et al., 2008). When combined with the
anticholinergic benactyzine, K027 and K048 were as efficacious
as trimedoxime and superior to pralidoxime, obidoxime, and HI-
6 in protecting mice from acute tabun-induced mortality (Kassa,
2006). Overall, with regard to nerve agents, K027 was efficacious
in vivo to protect from the toxic effects of tabun, but results
for cyclosarin and soman were unsatisfactory (Kuca et al., 2010;
Antonijevic et al., 2016).
When tested in rats exposed to the OPC pesticide
dichlorvos, K027 was more efficacious in reducing the
dichlorvos-induced lethal effects than the established oximes
pralidoxime, trimedoxime, obidoxime, and HI-6, when given
immediately after OPC administration (Antonijevic et al.,
2016) and reactivated dichlorvos-inhibited AChE in vivo more
efficiently than K203 (Antonijevic et al., 2018b). Compared with
pralidoxime, obidoxime, trimedoxime, and HI-6, K027 also
best reduced oxidative stress induced by dichlorvos poisoning
(Antonijevic et al., 2018a).
In a standardized experimental setting (shown in Tables 2,
3), we have quantified in vivo the protection conferred by K027
to reduce mortality induced by DFP and the pesticides ethyl-
paraoxon, methyl-paraoxon, and azinphos-methyl and compared
it with established (pralidoxime, obidoxime, trimedoxime, HI-6)
and experimental (K048, K053, K074, K075, K107, K108, K113)
oximes (Lorke et al., 2008b; Nurulain et al., 2009; Petroianu et al.,
2012; Lorke et al., 2013). The relative risk (RR) of death over
time was calculated according to Cox survival analysis (Cox,
1972) in rats that had been administered one of the OPCs at
three dosages (∼LD70, ∼LD100, ∼2 × LD70; Table 3) and
one of the oximes in a biologically defined dosage (50% of
LD01) within 1 min thereafter (Table 2). Cox regression model
allows for a statistical analysis of two different survival curves.
Instead of only looking at the survival at one predetermined time
point, the comparison of two survival curves measured over an
extended period provides additional information. Moreover, the
Cox proportional hazards model also allows for the analysis of
several factors of known or likely importance for the survival
of the animals (Gill, 1982). In our case, these covariates have
been OPC dose and type of treatment. Mortality data have been
compared and, for each of the seven time points, the respective
hazard ratios (relative risks of death) have been estimated using
the Cox proportional hazards model (Cox, 1972). Both OPC
dose (LD100, 2 × LD70, respectively, with LD70 the reference
category) and type of treatment (with the no treatment group
as the reference category) have been considered as categorical
variables. The RR equals 1 in animals that have only received
the OPC but no oxime treatment. A lower RR signifies superior
oxime protective efficacy.
K027 was the most efficacious protector from DFP-induced
toxicity, reducing the RR to 0.16 (Table 4), which was
significantly better than pralidoxime (RR = 0.62). Obidoxime
(RR = 0.19) and K048 (RR = 0.28) also significantly reduced DFP-
induced mortality (Lorke et al., 2008b). In animals exposed to
ethyl-paraoxon (Nurulain et al., 2009), best efficacy was again
observed for K027 (RR = 0.20), which was significantly better
than any other tested oxime. Significant reduction was also
observed for K048 (RR = 0.32), obidoxime (RR = 0.64), and
pralidoxime (RR = 0.78). K027 (RR = 0.58) and K048 (RR = 0.60)
were the only oximes investigated that were able to significantly
reduce methyl-paraoxon-induced mortality (Table 4); none of
the established oximes (pralidoxime, obidoxime, trimedoxime,
and HI-6) was efficacious against methyl-paraoxon (Petroianu
et al., 2012). When animals were exposed to azinphos-methyl
(Lorke et al., 2013), K027 also significantly reduced the relative
risk of death (RR = 0.26). A slightly, but not significantly,
better protection from the lethal effects of azinphos-methyl
was observed for K053 (RR = 0.22). Significant reduction
from azinphos-methyl-induced mortality was also achieved by
K048 (RR = 0.33), obidoxime (RR = 0.37), and pralidoxime
(RR = 0.39). In summary, when given immediately after exposure
to the OPCs DFP, ethyl-paraoxon, methyl-paraoxon, dichlorvos,
and azinphos-methyl, K027 is, by far, the most efficacious of
the tested oximes.
In addition, we have tested whether K027 is also able to
protect from OPC-induced toxicity if administered before OPC
exposure. Such pre-exposure treatment has been utilized in the
1991 Gulf War (Keeler et al., 1991; McCauley, 2006; Pope, 2006);
and thereafter, the US FDA has given its approval to administer
pyridostigmine orally, when soman exposure is imminent
(US Food and Drug Administration, 2003). Pretreatment with
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TABLE 4 | Protective efficacy of the tested oximes, assessed by Cox analysis (Cox, 1972) of the cumulative relative risk (RR) of death of animals exposed to the OPCs
diisopropylfluorophosphate = DFP, ethyl-paraoxon = paraoxon, azinphos-methyl or methyl-paraoxon and, within 1 min thereafter, treated with the experimental K-oximes
(K027, K048) or the established oximes (pralidoxime, obidoxime).
Organophosphorus compounds DFP1 Ethyl-paraoxon2 Azinphos-methyl3 Methyl-paraoxon4
Oxime Pralidoxime 0.62 ± 0.09 0.78 ± 0.06 0.39 ± 0.10 0.88 ± 0.10
Obidoxime 0.19 ± 0.07 0.64 ± 0.14 0.37 ± 0.10 0.93 ± 0.10
K027 0.16 ± 0.06 0.2 ± 0.06 0.26 ± 0.11 0.58 ± 0.14
K048 0.28 ± 0.06 0.32 ± 0.08 0.33 ± 0.07 0.6 ± 0.15
The cumulative RR was assessed by determining the area under the RR-time curve, adjusted for OPC dose (high/low). RR = 1 for the reference group (OPC alone,
no pretreatment); lower values reflect better protection. As illustrated by this table, by far the best RR-reducing efficacy is achieved by K027. 1Data from Lorke et al.
(2008b), 2data from Lorke and Petroianu (2009) and Nurulain et al. (2009), 3data from Lorke et al. (2013), and 4data from Petroianu et al. (2012). Bold Values: Oxime
treatment significantly (p ≤ 0.05) decreased the RR of OPC-induced death. Statistical differences were tested by the Mann–Whitney U test and a p-value ≤ 0.05 was
considered significant.
pyridostigmine is, however, only effective when atropine and
oxime are given after OPC exposure (Tuovinen et al., 1999;
Masson and Nachon, 2017), and frequent, although not
incapacitating side effects have been reported (McCauley, 2006;
Masson and Nachon, 2017). In contrast, physostigmine, which
is able to cross the blood–brain barrier, administered together
with the anticholinergic drug scopolamine, is more efficacious
prophylactically than pyridostigmine (Wetherell et al., 2007).
However, unwanted behavioral effects, which may affect decision-
making and adequate reactions in critical situations, have been
described as well (Masson and Nachon, 2017).
In search of an effective, practicable, acceptable, and
affordable pretreatment substance, we have evaluated in vivo the
prophylactic efficacy of a number of reversible cholinesterase
inhibitors (physostigmine, pyridostigmine, tacrine, ranitidine,
K027) by calculating the RR over time (Cox, 1972) in rats
that were first given the prophylactic agent at an equitoxic
dosage (25% of LD01; Table 5) and thereafter (30 min later)
one of the OPCs at three equitoxic dosages (∼LD70, ∼LD100,
∼2 × LD70; Table 3). When comparing the efficacy of different
prophylactic agents, they have to be administered in comparable
dosages. We decided to administer quantities according to in vivo
toxicity, that is, 25% of LD01 (= 25% of the dose at which 1%
of the animals die). This is an amount well tolerated by the
experimental animals (Lorke et al., 2011). We have previously
elaborated why equidosing according to in vitro parameters,
for example, IC50 of AChE inhibition, would ignore toxicities
unrelated to AChE inhibition and therefore produce false-
negative results (Lorke et al., 2011; Petroianu et al., 2013;
Lorke and Petroianu, 2019).
Such pretreatment is only feasible in situations when OPC
exposure can be anticipated, be it due to chemical warfare,
terrorist attacks, or exposure of rescue personal to contaminated
individuals. Given the diversity of OPCs that can possibly be
TABLE 5 | Chemical and biological parameters of the investigated inhibitors of AChE administered prophylactically before exposure to OPCs.
Reversible AChE Inhibitor Molecular Weight IC50 (µM) LD01 (µmol/rat) LD50 (µmol/rat) Injected Dose (µmol/rat)
Physostigmine 275.35 0.012 0.9 3.0 0.25
Pyridostigmine 261.12 0.33 3.7 7.2 1
Tacrine 250.00 0.2 16 21.5 4.00
Ranitidine 350.86 2.5 46 59 12.00
K027 446.16 414 250 350 60.00
Column 2 lists their molecular weights, column 3 their concentration necessary to inhibit 50% of human red blood cell AChE activity (IC50) (Lorke et al., 2011), column
4, their LD50 values for intraperitoneal (i.p.) application in rats, column 5 their LD01 values, and column 6 the doses injected i.p. for pretreatment 30 min before OPC
exposure to assess their efficacy to protect from OPC-induced mortality. The injected doses are approximately one fourth the LD01.
TABLE 6 | Protective efficacy of K027 and reversible AChE inhibitors (physostigmine, pyridostigmine, tacrine, ranitidine) administered prophylactically before exposure to
the OPCs ethyl-paraoxon = paraoxon, methyl-paraoxon or azinphos-methyl.
Organophosphorus compounds DFP1 Ethyl-paraoxon2 Methyl-paraoxon3 Azinphos-methyl4
Reversible AChE Inhibitors Physostigmine 0.02 ± 0.01 0.3 ± 0.15 0.39 ± 0.08 0.21 ± 0.5
Pyridostigmine 0.28 ± 0.09 0.76 ± 0.13 0.98 ± 0.11 0.37 ± 0.11
Tacrine 0.05 ± 0.03 0.67 ± 0.21 0.48 ± 0.07 0.29 ± 0.06
Ranitidine 0.41 ± 0.07 0.72 ± 0.16 0.87 ± 0.17 0.62 ± 0.29
K027 0.18 ± 0.12 0.34 ± 0.09 0.4 ± 0.13 0.15 ± 0.09
The reduction in the relative risk of death (RR) is calculated according to Cox (1972), with an RR = 1 for the reference group (OPC alone, no pretreatment). Lower values
reflect better protection. As illustrated by this table, the best RR-reducing efficacies were observed for K027 and physostigmine. 1Data from Lorke et al. (2011), 2data
from Petroianu et al. (2013), 3data from Lorke et al. (2012), and 4data from Petroianu et al. (2015). Bold values: Pretreatment significantly (p ≤ 0.05) decreased the RR.
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used for malicious purposes, ranging from an improvised bomb
containing pesticides fabricated by Hamas in 1997 (Dolnik
and Bhattacharjee, 2002; Kostadinov et al., 2010) to the recent
sarin gas attacks in the Syrian war (Dolgin, 2013; Pita and
Domingo, 2014), potential prophylactic agents need to be
tested against a broad range of chemically diverse OPCs. The
prophylactic efficacy of the individual pretreatment compounds
tested in our experiments varied depending on the OPCs
administered (Table 6), as previously reported for nerve agents
(Tuovinen et al., 1999).
Optimal protection from DFP-induced mortality (Lorke et al.,
2011) was afforded by physostigmine (RR = 0.02) and tacrine
(RR = 0.05), which were significantly (p ≤ 0.05) more efficacious
than any of the other tested AChE inhibitors, except K027
(RR = 0.18). Protection afforded by pyridostigmine (RR = 0.28)
and ranitidine (RR = 0.41) was also statistically significant, but
inferior to physostigmine and tacrine. When given before ethyl-
paraoxon exposure (Petroianu et al., 2013), best protection was
achieved by pretreatment with physostigmine (RR = 0.30) and
K027 (RR = 0.34), which were significantly more efficacious
than the other tested substances. Prophylactic administration of
tacrine (RR = 0.67), ranitidine (RR = 0.72), and pyridostigmine
(RR = 0.76) also significantly reduced ethyl-paraoxon-induced
mortality as compared with the non-treatment group (paraoxon
only, RR = 1; Table 6). In the case of methyl-paraoxon exposure
(Lorke et al., 2012), only pretreatment with physostigmine
(RR = 0.39), K027 (RR = 0.40), and tacrine (RR = 0.48)
significantly reduced mortality; pyridostigmine and ranitidine
did not significantly improve the RR. Mortality due to azinphos-
methyl (Petroianu et al., 2015) was best prevented by K027
(RR = 0.15) and physostigmine (RR = 0.21), followed by
tacrine (RR = 0.29), pyridostigmine (RR = 0.37), and ranitidine
(RR = 0.62), the latter being significantly less efficacious than
physostigmine, tacrine, and K027.
In summary, K027, when given prophylactically, very
efficaciously protects from exposure to a variety of OPCs, also
including terbufos sulfone (Lorke et al., 2014) and dicrotophos
(Lorke et al., 2017). We hypothesize that it acts by reactivating
phosphylated AChE rather than protecting the enzyme from
phosphorylation (Lorke and Petroianu, 2019).
CONCLUSION
K027 in vitro efficiently reactivates cholinesterase inhibited by a
broad range of organophosphates. It achieves maximum plasma
concentrations shortly after i.m. injection; and only a negligible
percentage is able to cross the blood–brain barrier. Due to its
low toxicity, K027 can be given in high dosages, which makes
it a very promising oxime not only for post-exposure treatment
but also for prophylactic administration, especially when brain
penetration is undesirable. Although K027 protects against a
broad range of pesticides and several nerve agents, it is not
efficacious against all nerve agents. Further improvement may be
achieved by combining K027 with other low-toxicity oximes with
a complementary spectrum (Worek et al., 2016).
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